CJMB
Callan JMB Inc.1.7700
+0.0600+3.51%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
8.18MP/E (TTM)
-Basic EPS (TTM)
-1.56Dividend Yield
0%Recent Filings
8-K
Insider trading policy amended
Callan JMB Inc. amended its insider trading policy on December 8, 2025, extending the blackout period start to the 20th day of each fiscal quarter's third month, lasting until after public disclosure of quarterly results. Board adopted the change to align restrictions with reporting timelines. Policy details in Exhibit 19.1. Routine governance tweak.
8-K
Interim CFO appointed
10-Q
Q3 FY2025 results
Callan JMB posted Q3 revenue of $1.45M, up 1% y/y yet down 12% YTD to $4.56M, with gross profit climbing 6% y/y to $493K on tighter costs. SG&A exploded 90% y/y to $2.37M from stock-based comp and public costs, fueling a $1.88M operating loss that doubled y/y; net loss hit $2.73M or $(0.61)/share, widened by $624K derivative hit and $229K ELOC expenses versus operating loss. Cash sits at $2.8M post-IPO and ELOC draws, with operating cash burning $3.89M YTD (derived) on receivables stretch. Leases bulked up to $2.1M liability. Customer concentration looms large.
8-K
Q3 results: revenue flat, loss widens
Callan JMB reported Q3 2025 revenue of $1.4 million, down slightly year-over-year from seasonal emergency services dips, yet gross profit held at $0.5 million while SG&A ballooned to $2.4 million on public company costs, driving a $1.9 million operating loss. Chicago contract extended through June 2026 with $1.5 million added funding, lifting total to $9.1 million. Diversifying boldly: food sampling entry, Texas drug equipment deal, India pharma sub. Cash sits at $2.8 million.
8-K
Q2 revenues dip amid expansions
Callan JMB reported Q2 2025 revenues of $1.7 million, down from $2.0 million year-over-year due to softer emergency preparedness demand, while SG&A expenses climbed to $2.0 million from public company costs and hires, yielding a $1.4 million operating loss. Key moves included a Revival partnership for integrated health product supply chains, an India subsidiary launch for cold chain pharma logistics, and a Chicago contract extension adding $1.5 million to reach $9.1 million total through June 2026. Expansion targets GLP-1 drugs and compounding pharmacies. Risks include execution in new markets.
IPO
Website
Employees
Sector
Industry
CCEL
Cryo-Cell International, Inc.
3.80+0.06
CHRW
C.H. Robinson Worldwide, Inc.
159.04+1.43
CTNT
Cheetah Net Supply Chain Servic
1.39+0.00
CVLG
Covenant Logistics Group, Inc.
23.27+0.16
CYRX
CryoPort, Inc.
9.24+0.00
JANL
Janel Corp.
34.00+0.00
JBHT
J.B. Hunt Transport Services, I
196.76-0.84
JYD
Jayud Global Logistics Limited
3.54-0.02
LSTR
Landstar System, Inc.
144.57-1.78
SFWL
Shengfeng Development Limited
1.08+0.28